• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.微生物群移植可恢复复发性艰难梭菌感染患者的正常粪便胆汁酸组成。
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9. doi: 10.1152/ajpgi.00282.2013. Epub 2013 Nov 27.
2
Recurrent Clostridium difficile infections: the importance of the intestinal microbiota.复发性艰难梭菌感染:肠道微生物群的重要性。
World J Gastroenterol. 2014 Jun 21;20(23):7416-23. doi: 10.3748/wjg.v20.i23.7416.
3
Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth.粪便微生物群移植后结肠胆汁酸组成的变化足以控制艰难梭菌的萌发和生长。
PLoS One. 2016 Jan 20;11(1):e0147210. doi: 10.1371/journal.pone.0147210. eCollection 2016.
4
Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent infection.与复发性感染的粪便微生物群移植相关的宏基因组、代谢组和脂质组变化。
mSphere. 2024 Oct 29;9(10):e0070624. doi: 10.1128/msphere.00706-24. Epub 2024 Oct 8.
5
Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection.复发性艰难梭菌感染患者粪便微生物群移植后短链脂肪酸和胆汁酸代谢的恢复
Anaerobe. 2018 Oct;53:64-73. doi: 10.1016/j.anaerobe.2018.04.001. Epub 2018 Apr 12.
6
Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.接受粪菌移植治疗复发性艰难梭菌感染患者的微生物组动态变化。
PLoS One. 2013 Nov 26;8(11):e81330. doi: 10.1371/journal.pone.0081330. eCollection 2013.
7
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.复发性艰难梭菌感染和/或溃疡性结肠炎患者单次供体粪便微生物群移植的纵向微生物组分析
PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.
8
Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.粪便微生物移植治疗免疫功能低下患者的艰难梭菌感染。
Am J Gastroenterol. 2014 Jul;109(7):1065-71. doi: 10.1038/ajg.2014.133. Epub 2014 Jun 3.
9
Longitudinal Bile Acid Composition Changes Following Faecal Microbiota Transplantation for Clostridioides difficile Infection in Children With and Without Underlying Inflammatory Bowel Disease.儿童艰难梭菌感染行粪菌移植后胆汁酸组成的纵向变化:有无炎症性肠病的比较。
J Crohns Colitis. 2023 Aug 21;17(8):1364-1368. doi: 10.1093/ecco-jcc/jjad057.
10
Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.通过恢复肠道微生物群产生的正戊酸盐来抑制艰难梭菌的生长。
Gastroenterology. 2018 Nov;155(5):1495-1507.e15. doi: 10.1053/j.gastro.2018.07.014. Epub 2018 Jul 17.

引用本文的文献

1
Effect of fecal microbiota transplantation on gut microbiota functional profile in recipients of allogeneic hematopoietic cell transplantation.粪便微生物群移植对异基因造血细胞移植受者肠道微生物群功能谱的影响。
Gut Microbes. 2025 Dec;17(1):2551882. doi: 10.1080/19490976.2025.2551882. Epub 2025 Aug 27.
2
The gut virome in association with the bacteriome in gastrointestinal diseases and beyond: roles, mechanisms, and clinical applications.胃肠道疾病及其他情况下与细菌群落相关的肠道病毒组:作用、机制及临床应用
Precis Clin Med. 2025 May 28;8(2):pbaf010. doi: 10.1093/pcmedi/pbaf010. eCollection 2025 Jun.
3
Host origin of microbiota drives functional recovery and clearance in mice.微生物群的宿主来源驱动小鼠的功能恢复和清除。
mBio. 2025 Jun 2:e0110825. doi: 10.1128/mbio.01108-25.
4
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy for prevention of recurrent infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial.结肠镜检查给药的粪便微生物群制剂live-jslm(REBYOTA)预防复发性感染的安全性和有效性:单臂IIIb期试验CDI-SCOPE的8周结果
Therap Adv Gastroenterol. 2025 Apr 22;18:17562848251339697. doi: 10.1177/17562848251339697. eCollection 2025.
5
Effects of fermented bamboo fiber on intestinal health and fecal pollutants in weaned piglets.发酵竹纤维对断奶仔猪肠道健康和粪便污染物的影响
Front Nutr. 2025 Mar 31;12:1538560. doi: 10.3389/fnut.2025.1538560. eCollection 2025.
6
Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.粪便微生物群移植:应用场景、疗效预测及影响供体-受体相互作用的因素
Front Microbiol. 2025 Mar 25;16:1556827. doi: 10.3389/fmicb.2025.1556827. eCollection 2025.
7
Leveraging strain competition to address antimicrobial resistance with microbiota therapies.利用菌株竞争通过微生物群疗法解决抗生素耐药性问题。
Gut Microbes. 2025 Dec;17(1):2488046. doi: 10.1080/19490976.2025.2488046. Epub 2025 Apr 7.
8
Nonobstructive Recurrent Cholangitis After Hepatobiliary Tract Diversion in Patients With Surgically Altered Anatomy: A Challenging Problem.解剖结构改变患者行肝胆管改道术后的非梗阻性复发性胆管炎:一个具有挑战性的问题
ACG Case Rep J. 2025 Mar 5;12(3):e01639. doi: 10.14309/crj.0000000000001639. eCollection 2025 Mar.
9
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.肠道菌群失调相关疾病的粪便微生物群移植研究进展
Adv Sci (Weinh). 2025 Apr;12(13):e2413197. doi: 10.1002/advs.202413197. Epub 2025 Feb 27.
10
Fiber- and acetate-mediated modulation of MHC-II expression on intestinal epithelium protects from Clostridioides difficile infection.纤维和乙酸盐介导的肠道上皮细胞MHC-II表达调节可预防艰难梭菌感染。
Cell Host Microbe. 2025 Feb 12;33(2):235-251.e7. doi: 10.1016/j.chom.2024.12.017. Epub 2025 Jan 17.

本文引用的文献

1
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.社区获得性艰难梭菌感染的流行病学,2009 年至 2011 年。
JAMA Intern Med. 2013 Jul 22;173(14):1359-67. doi: 10.1001/jamainternmed.2013.7056.
2
Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection.艰难梭菌发芽受体 CspC 对胆汁酸的识别对于建立感染很重要。
PLoS Pathog. 2013 May;9(5):e1003356. doi: 10.1371/journal.ppat.1003356. Epub 2013 May 9.
3
Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.肠功能、粪便未结合初级和次级胆酸以及肠易激综合征患者的结肠传输。
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1270-1275.e1. doi: 10.1016/j.cgh.2013.04.020. Epub 2013 Apr 30.
4
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.艰难梭菌感染的诊断、治疗和预防指南。
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26.
5
High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria.高通量 DNA 序列分析揭示了先前冷冻粪便细菌移植后肠道微生物群的稳定定植。
Gut Microbes. 2013 Mar-Apr;4(2):125-35. doi: 10.4161/gmic.23571. Epub 2013 Jan 18.
6
Duodenal infusion of donor feces for recurrent Clostridium difficile.经十二指肠输注供体粪便治疗复发性艰难梭菌感染。
N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
7
Emergence and global spread of epidemic healthcare-associated Clostridium difficile.传染病相关艰难梭菌的出现和全球传播。
Nat Genet. 2013 Jan;45(1):109-13. doi: 10.1038/ng.2478. Epub 2012 Dec 9.
8
Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing.基于 16S rRNA 基因深度测序,探究粪便微生物群移植相关多样性变化。
mBio. 2012 Oct 23;3(5):e00338-12. doi: 10.1128/mBio.00338-12.
9
Current status of Clostridium difficile infection epidemiology.艰难梭菌感染流行病学的现状。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S65-70. doi: 10.1093/cid/cis319.
10
Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection.标准化的粪便微生物群移植冷冻制剂用于复发性艰难梭菌感染。
Am J Gastroenterol. 2012 May;107(5):761-7. doi: 10.1038/ajg.2011.482. Epub 2012 Jan 31.

微生物群移植可恢复复发性艰难梭菌感染患者的正常粪便胆汁酸组成。

Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

机构信息

Department of Soil, Water, and Climate and The BioTechnology Institute, University of Minnesota, St. Paul, Minnesota;

出版信息

Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9. doi: 10.1152/ajpgi.00282.2013. Epub 2013 Nov 27.

DOI:10.1152/ajpgi.00282.2013
PMID:24284963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3920123/
Abstract

Fecal microbiota transplantation (FMT) has emerged as a highly effective therapy for refractory, recurrent Clostridium difficile infection (CDI), which develops following antibiotic treatments. Intestinal microbiota play a critical role in the metabolism of bile acids in the colon, which in turn have major effects on the lifecycle of C. difficile bacteria. We hypothesized that fecal bile acid composition is altered in patients with recurrent CDI and that FMT results in its normalization. General metabolomics and targeted bile acid analyses were performed on fecal extracts from patients with recurrent CDI treated with FMT and their donors. In addition, 16S rRNA gene sequencing was used to determine the bacterial composition of pre- and post-FMT fecal samples. Taxonomic bacterial composition of fecal samples from FMT recipients showed rapid change and became similar to the donor after the procedure. Pre-FMT fecal samples contained high concentrations of primary bile acids and bile salts, while secondary bile acids were nearly undetectable. In contrast, post-FMT fecal samples contained mostly secondary bile acids, as did non-CDI donor samples. Therefore, our analysis showed that FMT resulted in normalization of fecal bacterial community structure and metabolic composition. Importantly, metabolism of bile salts and primary bile acids to secondary bile acids is disrupted in patients with recurrent CDI, and FMT corrects this abnormality. Since individual bile salts and bile acids have pro-germinant and inhibitory activities, the changes suggest that correction of bile acid metabolism is likely a major mechanism by which FMT results in a cure and prevents recurrence of CDI.

摘要

粪便微生物群移植(FMT)已成为治疗抗生素治疗后发生的难治性、复发性艰难梭菌感染(CDI)的一种非常有效的疗法。肠道微生物群在结肠胆汁酸代谢中起着关键作用,而胆汁酸反过来又对艰难梭菌细菌的生命周期有重大影响。我们假设复发性 CDI 患者的粪便胆汁酸组成发生改变,并且 FMT 使其正常化。对接受 FMT 治疗的复发性 CDI 患者及其供体的粪便提取物进行了常规代谢组学和靶向胆汁酸分析。此外,还使用 16S rRNA 基因测序来确定 FMT 前后粪便样本的细菌组成。FMT 受者粪便样本的分类细菌组成迅速变化,并在该过程后变得与供体相似。FMT 前粪便样本含有高浓度的初级胆汁酸和胆盐,而次级胆汁酸几乎无法检测到。相比之下,FMT 后粪便样本主要含有次级胆汁酸,非 CDI 供体样本也是如此。因此,我们的分析表明 FMT 导致粪便细菌群落结构和代谢组成正常化。重要的是,复发性 CDI 患者的胆汁盐和初级胆汁酸向次级胆汁酸的代谢被破坏,而 FMT 纠正了这种异常。由于个体胆汁盐和胆汁酸具有促发芽和抑制活性,这些变化表明胆汁酸代谢的纠正可能是 FMT 导致治愈和预防 CDI 复发的主要机制。